Sonnet BioTherapeutics has made headlines with its recent announcement regarding the postponement of its merger vote with Hyperliquid Strategies Inc. and Rorschach I LLC. Originally scheduled for an earlier date, the vote has now been rescheduled to December 2, 2025, as the company works to secure the necessary shareholder approval. The publication provides the following information:
Delay in Merger Vote
The decision to delay the merger vote comes after Sonnet BioTherapeutics initially garnered over 95% support from shareholders but ultimately failed to meet the quorum requirements needed for the vote to proceed. This merger is poised to create a substantial $1 billion digital asset treasury, which could have a profound impact on financial markets and investment strategies within the cryptocurrency sector.
Market Speculation
Market participants are now speculating on the implications of this delay, as it raises questions about the future direction of the merger and its potential effects on the industry. Shareholders are being urged to actively participate in the upcoming meeting to ensure that their voices are heard and that the merger process is strategically guided to benefit all stakeholders involved.
Inbeom, the founder of BugsCoin, recently addressed the ongoing merger discussions with ADEN, highlighting the importance of verified information amidst speculation. For more details, see the full update here.
